Campath Antitrust Order Focuses On Off-Label Use In Organ Transplant Market
This article was originally published in The Pink Sheet Daily
Executive Summary
Schering AG will take over sole rights for development and marketing of Campath as acute therapy for solid organ transplant rejection as a result of the Genzyme/Ilex merger
You may also be interested in...
Genzyme Completes Acquisition Of Ilex, Awaits Clolar Launch
Genzyme closes $1 bil. deal the day after receiving Federal Trade Commission approval. Clolar could be Genzyme's first direct presence in oncology therapeutic market; FDA's user fee deadline is Dec. 30.
Medicare Reaffirms Faith In Formulary Review Process Ahead Of Part D Changes
Dramatic transformation in the US Medicare Part D benefit design does not require any changes to CMS’ overall approach to reviewing formulary submissions from private drug plan sponsors, the agency says in its final guidance implementing the design changes for 2025.